Non-alcoholic fatty liver disease (NAFLD) is a multisystem disease that not only affects the liver with the development of complications up to cirrhosis, but also associated by an increased risk of developing such diseases/conditions such as diabetes mellitus, cardiovascular pathology, metabolic syndrome, as well as oncological diseases. In this regard, NAFLD represents a medical and social burden associated with high mortality and a decrease in the quality of life of patients. To increase the awareness of physician about this pathology and a systematic approach to pharmacotherapy, in 2022 For the first time in Russia, a National Consensus on the management of adult patients with NAFLD has been released. According to the consensus, the criteria for rational drug therapy are not only the effect on slowing the progression of liver damage up to the regression of steatosis, steatohepatitis and fibrosis, but also a decrease in cardiometabolic risk factors. Currently, only ursodeoxycholic acid (UDCA) meets these requirements. In addition, this drug has a synergistic lipid-lowering effect when combined with statins, which makes it the drug of choice for the treatment of NAFLD at any stage. Considering the high efficiency and large evidence base, UDCA is included in the recommendations on NAFLD and combined pathology by various medical associations: gastroenterological, cardiological, therapeutic.

Keywords: liver fibrosis, ursodeoxycholic acid, insulin resistance, non-alcoholic fatty liver disease, liver steatosis, obesity, dyslipidemia